ANTIMICROBIAL MATERIAL

Abstract

The present invention relates to antimicrobial materials comprising copper and zinc incorporated into or coated on a substrate material, wherein the substrate comprises a rubber component. The present invention also relates to methods of obtaining said antimicrobial materials.

Claims

1. An antimicrobial material comprising a substrate and a metal component, wherein the metal component comprises chemically bonded copper and zinc and wherein the substrate comprises a rubber component.

2. The antimicrobial material according to claim 1, wherein the rubber is a silicone rubber.

3. The antimicrobial material according to claim 1, wherein the copper and zinc form an alloy.

4. The antimicrobial material according to claim 1, wherein the metal component further includes any metal selected from the group consisting of zirconium, silver, gold, palladium, platinum, iridium, aluminium, nickel, tungsten, molybdenum, tantalum, titanium, iodine and/or any alloys thereof.

5. The antimicrobial material according to claim 1, wherein the metal component further includes one or more salts of any of zirconium, copper, zinc, silver, gold, palladium, platinum, iridium, aluminium, nickel, tungsten, molybdenum, tantalum, titanium and/or iodine.

6. The antimicrobial material according to claim 1, wherein the metal component comprises particles measuring 3-50 μm, preferably 15-30 μm.

7. The antimicrobial material according to claim 1, wherein the metal component comprises at least 60% copper.

8. The antimicrobial material according to claim 1, wherein the metal component comprises 75-80% copper.

9. The antimicrobial material according to claim 1, wherein the metal component comprises 20-25% zinc.

10. The antimicrobial material according to claim 1, wherein the metal component is interspersed throughout the substrate and/or wherein the metal component forms a coating layer on a surface of the substrate.

11. The antimicrobial material according to claim 10, wherein the coating layer has antimicrobial properties and is arranged such that, in use, the surface comes into contact with a potentially contaminated surface.

12. The antimicrobial material according to claim 1, wherein the substrate comprises a polymer-based substrate, preferably wherein the polymer is polyurethane, polypropylene and/or collagen; and more preferably wherein the polymer is comprised in a hydrogel.

13. The antimicrobial material according to claim 1, wherein the rubber component is interspersed or impregnated throughout the substrate and/or wherein the rubber component forms a coating layer on a surface of the substrate.

14. The antimicrobial material according to claim 1, wherein 3-15% of said material by weight consists of the metal component.

15. The antimicrobial material according to claim 1, wherein the material further includes chelating compounds, magnesium sulphate and/or a copper peptide.

16. A medical device comprising or formed from the antimicrobial material of claim 1.

17. The medical device according to claim 16, wherein the medical device is a catheter, a nasogastric tube, a cannula or a laparoscope tube.

18. A method of manufacturing an antimicrobial material comprising a substrate and a metal component, wherein the metal component comprises chemically bonded copper and zinc, and wherein the substrate comprises a rubber component, the method comprising the steps of: a) combining copper and zinc to produce said metal component; b) heating the metal component to a molten state; c) disrupting said molten state with a high velocity gas, and; d) combining the disrupted metal component with the substrate.

19. The method according to claim 18, wherein the rubber component is a silicone rubber.

20. The method according to claim 18, wherein the metal component is reduced in size prior to step (b) using a mechanical attrition process.

21. The method according to claim 18, wherein step (c) results in a powdered form of said metal component.

22. The method according to claim 18, wherein the metal component is heated at step (b) to 2000 degrees centigrade.

23. An antimicrobial material according to obtainable by the method of claim 18 or a medical device comprising said material.

24. A method of preventing or treating a wound infection comprising utilising the antimicrobial material of claim 1 or a medical device comprising said material in a medical or veterinary setting.

Description

DETAILED DESCRIPTION

[0022] The following description is presented to enable any person skilled in the art to make and use the invention. Various modifications to the disclosed embodiments will be readily apparent to those skilled in the art.

[0023] In a first aspect, the present invention provides an antimicrobial material comprising a substrate and a metal component, wherein the metal component comprises chemically bonded copper and zinc and wherein the substrate comprises a rubber component.

[0024] The term ‘antimicrobial material’ refers to a material having antimicrobial properties, for example biocidal or biostatic properties. In the context of the present invention, the term tiocidar is understood to mean a substance that can destroy, deter, render harmless or exert a controlling effect on a pathogenic organism, whereas the term ‘biostatic’ refers to a substance which can inhibit the growth or multiplication of an organism, for example a microorganism. It is envisaged that the present invention will be useful against any microorganism, for example any bacteria, virus and/or fungi. In particular, it is envisaged that bacteria in the Genus Staphylococcus and Klebsiella, fungi in the Genus Candida, and members of the Coronaviridae family, will be sensitive to the presently described materials.

[0025] The present invention provides materials with surprisingly high antimicrobial activity. Products, such as medical devices, incorporating the materials of the invention will reduce incidences of septicaemia and infection. The present invention is particularly useful in the prevention of infections associated with commonly used medical devices, for example, catheters, nasogastric tubes, cannulas and/or laparoscopic tubes, where microbes can travel from the external environment via the medical device to the subject and cause infection, or where microorganisms present on the skin or other mucosal surfaces can colonise the device and cause a biofilm to form. This prevention is particularly important in instances where the medical device is used over a prolonged period of time, therefore increasing the risk of the subject developing an infection.

[0026] By ‘substrate’, we intend any suitable structural material to which the metal component can be incorporated, thereby providing a physical medium on or in which the metal component may be deployed. The substrate of the present invention comprises a rubber component. Examples of suitable rubber varieties that could be used in the present invention include natural rubber (latex), neoprene rubber, silicone rubber and nitrile rubber.

[0027] Preferably, the rubber component is a silicone rubber. Silicone, also known as polysiloxane, is any polymer that includes a synthetic compound made up of repeating units of siloxane. Siloxane is a chain of alternating silicon atoms and oxygen atoms, combined with carbon, hydrogen and sometimes with other elements. The use of silicone rubber is desirable due to a number of advantageous properties; general non-reactiveness, high stability, and high resistance to extreme environments, such as extreme heat and cold (for example, −55 degrees to 300 degrees Celsius). The types of silicone envisaged to be used in the present invention are liquid silicone rubber (LSR) and high consistency silicone rubber (HCR or gum stock). The skilled person will recognise that the type of silicone rubber to be chosen depends on both the manufacturing process and the end application. For example, the use of HCR may be more appropriate when looking to create medical devices with complex shapes or thin walls.

[0028] Examples of suitable polymers that may form the basis for the polymer-based material substrate include the synthetic polymers polyurethane and polypropylene and the naturally occurring matrix polymer collagen. The substrate may preferably be a polymer based hydrogel. The polymer used in the hydrogel may be any polymer according to the disclosure. The term ‘polymer based hydrogels’ refers to polymer networks which are extensively swollen with water. Examples of the latter, which could be used in the present invention, include P-DERM® Hydrogels and Nanorestore Gels®.

[0029] By ‘chemically bonded’, we intend any lasting attraction between atoms, ions or molecules of copper and zinc as a result of ionic, covalent or metallic bonding. Accordingly, this may include copper alloys or copper compounds, including but not limited to copper salts and oxides.

[0030] Preferably, the metal component of the antimicrobial material comprises a copper-zinc alloy. An alloy is understood to be a mixture of two elements, one of which is a metal. In this instance, the copper-zinc alloy is understood to be a substitutional alloy, whereby the atoms of the two components may replace each other within the same crystal structure, creating a sea of delocalised electrons.

[0031] A skilled person would recognise that in order to produce the required alloy, elemental copper and zinc are mixed together in their molten form before solidifying as a new and distinct chemical entity. In one embodiment, it is envisaged that additional metals and compounds thereof, e.g. salts, may be incorporated into the material or metal component. These metals include, but are not limited to, zirconium, copper, zinc, silver, gold, palladium, platinum, iridium, aluminium, nickel, tungsten, molybdenum, tantalum, titanium, iodine. It is understood that the latter compounds may be additional components to the claimed material which contribute to a further enhancement of the antimicrobial properties of the material.

[0032] The use of an alloy, as opposed to the pure form of the metal or associated compounds, results in a number of advantageous properties compared to the use of pure copper. Specifically, a copper-zinc alloy benefits from the extra antimicrobial properties of zinc, excellent malleability/castability and high strength.

[0033] The particles of the metal component are expected to measure between 10-80 μm, with the preferred size being anywhere from 15-30 μm. A finely ground powder releases more ions compared to a course powder, the released ions of which may be responsible for the antimicrobial effect.

[0034] It is envisaged that the metal component will contain at least 60% copper. This formulation will have enhanced antimicrobial properties. Preferably, the metal component comprises 75-80% copper with a corresponding amount of 20-25% zinc. As outlined above, the metal component may additionally contain other element(s), compounds and salts thereof. These additions may confer beneficial properties to the claimed material. For example, additional components may further enhance the antimicrobial actions or allow for increased longevity of the claimed product.

[0035] In one embodiment of the present invention, the metal component and/or the rubber may be interspersed throughout the substrate. By ‘interspersed’ we intend that the metal component is scattered between particles/molecules of the substrate material. Such a configuration could alternatively be described as ‘impregnation’. The metal component may be evenly or unevenly dispersed throughout the substrate material. A skilled person would understand that the degree of interspersion, dispersion and/or impregnation may depend on the polymer type used in the manufacture of the substrate material and/or the process used to apply the metal component and/or the rubber to the substrate. In a further embodiment of the present invention, the metal component and/or the rubber may be present as a coating layer on the surface of the substrate. Where a coating layer is present, it is expected that the coating will be arranged such that, in use, it comes into contact with a potentially contaminated surface/wound to exert its antimicrobial effect. The coating layer may be any thickness. Additionally, the coating layer is understood to be present on at least one surface of the substrate, but may be present on all substrate surfaces. The coating layer may either partially coat or completely coat a particular surface of the substrate. The degree of coverage of the coating layer will be dependent on the intended use of the claimed product.

[0036] It is envisaged that the substrate may be a polymer-based substrate. A polymer is a large molecule composed of smaller repeated subunits. Preferably, the substrate used in the present invention may include polyurethane, polypropylene, and/or collagen based polymers. The substrate may include polymer based hydrogels or polymer based hydrocolloids, according to the disclosure. Both thermosetting and thermoplastic polyurethanes may be suitable for use in the present invention. However, it is envisaged that any material suitable for stably maintaining the metal component and/or rubber may be used alone or in combination as substrates according to the present invention. For example, materials such as wool, cotton, leather, flax, ramie, silk, hemp, bamboo, jute, rayon, neoprene, elastane, rubber, polyester may be suitable as substrates as appropriate. In some instances, it is understood that the substrate may be a combination of different types of polymer. Such combinations may confer additional advantageous properties on the substrate for a desired purpose or to facilitate manufacture and storage. In particular, it is envisaged that alginates and cellulose could be incorporated into the substrate to enhance absorbency, flexibility and comfort. The skilled person will recognise that polymer-based hydrogels are particularly beneficial for use in wound dressings due to the presence of hydrophilic functional groups. This feature enables the control of moisture at a particular surface.

[0037] Preferably, the substrate may include the following ingredients following manufacture: [0038] a) Sodium carboxymenthylcellulose [0039] b) Surfactant [0040] c) Glycerine [0041] d) Citric Acid [0042] e) The selected polymer, and [0043] f) The selected form of rubber (preferably silicone rubber)

[0044] Examples of suitable surfactants include sodium stearate, dioctyl sodium sulfosuccinate and perfluorooctanesulfonate. Suitable surfactants may belong to any of the following groups: anionic, cationic, non-ionic or zwitterionic surfactants. The citric acid element may be substituted with other weak acids if required, for example, acetic acid, lactic acid and phosphoric acid. Part e) of the above list may be substituted with any of the aforementioned polymers. Preferably, the polymer of choice is used in isolation; however different polymers may be used in combination if the end antimicrobial agent is deemed more effective and remains 68.5% of the substrate composition.

[0045] Preferably, 3-15% of the substrate by weight consists of the metal component. For example, 3-5%, 3-6%, 3-7%, 3-8%, 3-9%, 3-10%, 3-11%, 3-12%, 3-13%, 3-14%, 5-6%, 5-7%, 5-8%, 5-9%, 5-10%, 5-11%, 5-12%, 5-13%, 5-14%, 10-11%, 10-12%, 10-13%, 10-14%.

[0046] Also envisaged is the inclusion of further additives to the material to improve the antimicrobial properties, if required. These additives may include chelating agents, magnesium sulphate and/or a copper peptide. These additives may be incorporated into the substrate at 0.1 to 1% by weight, for example about 0.5% by weight. The term “chelating agent” is used to describe a substance that can form several bonds with a single metal ion thus forming a more stable complex. A skilled person would recognise the action of such substances could enhance the antimicrobial properties.

[0047] The present invention may be effective when it comes into contact with any contaminated surface. In a preferred embodiment, the present invention may be incorporated into a medical device. In yet a further preferred embodiment, the present invention may be incorporated in a catheter, nasogastric tube, cannula, or laparoscopic tubing.

[0048] By the terms ‘catheter’, ‘nasogastric tube’, ‘cannula’ and ‘laparoscopic tubing’, we intend any tubing that can be inserted into a subject (human or animal) for the purpose of treating diseases, feeding, performing a surgical procedure, for example, laparoscopic surgery, or for performing physiological functions that the subject is currently unable to manage independently, for example, emptying the bladder of urine. Examples include, but are not limited to, urinary catheters, drainage of fluid collections (abscesses), drainage of air/fluid from around the lungs, administration of intravenous fluids (blood, medication, nutrition), collection of bodily fluids (for example, blood samples, cerebral spinal fluid samples), use in angioplasty and angiography, administration of medication (for example, anaesthetic) in the epidural or subarachnoid space, tracheal tubing and an umbilical line.

[0049] The skilled person will appreciate that the properties of the tubing, for example, the degree of flexibility, will be dependent upon the intended application.

[0050] The present invention provides a high level of antimicrobial activity and therefore has wide-reaching applications. The present invention includes an infection control product comprising the antimicrobial material of the invention. Such a product may have utility in the healthcare setting, most often as a medical material. By ‘infection control product’ we intend any product that treats, prevents or attenuates the development and/or spread of infections. Examples of such products include wound dressings, bandages, medical devices, drug containers and personal protective clothing for infection protection.

[0051] In a second aspect, the present invention provides a method of manufacturing an antimicrobial material comprising a substrate and a metal component, wherein the metal component comprises chemically bonded copper and zinc and the substrate comprises a rubber component. The method comprises the steps of a) combining copper and zinc to produce said metal component; b) heating the metal component to a molten state; c) disrupting said molten state with a high velocity gas, and; d) combining the disrupted metal component with a substrate, wherein the substrate comprises a rubber component as set out herein. Preferably, the rubber component is a silicone rubber.

[0052] Thus, one method of producing the metal component of the invention may involve a plasma or gas atomisation process. It is envisaged that powdered forms of the metals may be used in the method of the invention but other forms could be appropriate as would be understood by a person of skill in the art.

[0053] It is envisaged that the plasma or gas atomisation process will result in a powdered form of the metal component, which can be combined with the substrate as appropriate, as would be understood by a person of skill in the art.

[0054] In a preferred embodiment, prior to the commencement of the plasma or gas atomisation process, the metal component may optionally be reduced in size via the use of a mechanical attrition process. By ‘mechanical attrition’ we intend any process by which the result is the gradual breakdown of the metal component into smaller elements. This process can be achieved via the use of a number of attrition devices, including but not limited to: attrition mill, horizontal mill, 1D vibratory mill, 3D vibratory mill and planetary mill. All of the above devices result in a reduction in size due to the energy imparted to the sample during impacts between the milling media. Thus, metallic forms copper and zinc may be ground down to an appropriate form for us in the methods of the invention.

[0055] Once the copper and zinc have been combined, the atomisation process may proceed. As would be understood by a person of skill in the art, the means of combining the copper and zinc may differ depending on the atomisation process to be utilised.

[0056] Plasma atomisation requires the metal component to be in a wire form to be used as a feedstock. This is typically a wire of an alloy of the metal component, as would be understood by a person of skill in the art. Contrary to conventional gas atomisation, plasma atomisation uses plasma torches to instantaneously melt and atomise the wire in a single step. A cooling tower is then used to convert the droplets formed into a spherical powder.

[0057] Alternatively, conventional gas atomisation may be used. This may involve the heating of the copper-zinc metal component to approximately 2000° C. to produce a molten state of said component. By ‘molten state’ we intend the liquid form of said metal component when exposed to high temperatures. As would be understood by a person skilled in the art, a high velocity gas stream may flow through an expansion nozzle, siphoning the molten metal component from an input chamber. Examples of gases that can be used in this process include nitrogen, argon, helium or air. The skilled person will recognise that it is possible to use more than one gas in this process and the preferred gas or gas mixture will be inert/unreactive. The choice of gas used will depend on the desired end disrupted metal (powder) characteristics. To provide a suitable metal component for use in materials of the invention, high velocities of inert gas may be required. A skilled person will recognise that the velocity required will differ depending on the gas used but are likely to be within the range of 100-2000 m/s. This process disrupts the liquid stream of molten metal and results in the production of fine particles, culminating in the desired powdered form of the metal component. Obtaining the powdered form via the above methods has a number of advantages; production of highly spherical particles, low oxygen content and adaptability to the production of copper and zinc. A skilled person will also recognise that alternative methods of producing the metal powder may exist which could be employed to achieve the same effect.

[0058] To produce the final antimicrobial material, the metal component is added to the substrate. Specifically, the metal powder is added in small quantities until the entirety of the product is transferred to the substrate. The resulting composition is mixed at room temperature (20-22° C.) for 2 hours at 350 rpm and subsequently allowed to solidify.

[0059] The skilled person will be aware of the various methods by which the rubber component can be introduced into the present invention to create a medical device to the desired specification. For example, there are various molding processes that can be utilised. These include liquid injection molding, transfer molding, compression molding, micromolding or overmolding. Alternatively, extrusion processes may be employed.

[0060] The present invention also provides a method of preventing or treating an infection comprising utilising the antimicrobial material of the invention in a medical or veterinary setting.

[0061] In order that the invention may be more clearly understood embodiments thereof will now be described by way of example.

Example 1

[0062] Test of the antimicrobial material on two different strains of bacteria: Staphylococcus aureus and Klebsiella pneumoniae.

[0063] Each test organism was prepared to approximately 1×10.sup.5 colony forming units (CFU)/mL in 0.85% NaCl. For each sample, five replicates were inoculated with each test organism. The inocula were enumerated using pour plates of Tryptone Soya Agar (TSA) at the point of inoculation. The inoculated samples were held for 24 hours at 24° C.±1° C. and >95% humidity. Following the exposure time, the inoculated test pieces were aseptically removed to 9 ml diluent. This was vigorously shaken to ensure thorough resuspension of any remaining test organisms. The resulting suspension was plated out in TSALT (TSA supplemented with 0.3% soya lecithin and 3% Tween 80). Plates were incubated at 31° C.±1° C. for at least 5 days.

TABLE-US-00001 TABLE 1 Effect of 0% CuZn foam material on two types of bacteria: Staphylococcus aureus and Klebsiella pneumoniae. 24-hour contact time Recovery per test Log.sub.10 Mean Log.sub.10 piece (CFU) reductions reductions S. S. S. aureus K. aureus K. aureus K. ATCC pneumoniae ATCC pneumoniae ATCC pneumoniae Sample: Replicate 6538 NCO9633 6538 NCO9633 6538 NCO9633 Inoculum — 1.1 × 10.sup.5 9.6 × 10.sup.4 — — — — (zero time) 0% CuZn 1 5.0 × 10.sup.3 >1.0 × 10.sup.6 1.34 0 1.32 0 Foam 2 5.6 × 10.sup.3 >1.0 × 10.sup.6 1.29 0 3 4.7 × 10.sup.3 >1.0 × 10.sup.6 1.37 0 4 5.7 × 10.sup.3 >1.0 × 10.sup.6 1.28 0 5 5.0 × 10.sup.3 >1.0 × 10.sup.6 1.34 0

TABLE-US-00002 TABLE 2 Effect of 3% CuZn foam material on two types of bacteria: Staphylococcus aureus and Klebsiella pneumoniae. 24-hour contact time Recovery per test Mean Log.sub.10 piece (CFU) Log.sub.10 reductions reductions S. S. S. aureus K. aureus K. aureus K. ATCC pneumoniae ATCC pneumoniae ATCC pneumoniae Sample: Replicate 6538 NCO9633 6538 NCO9633 6538 NCO9633 Inoculum — 2.8 × 10.sup.5 2.4 × 10.sup.5 — — — — (zero time) 3% CuZn 1 <10 <10 >4.45 >4.38 >4.45 >4.38 Foam 2 <10 <10 >4.45 >4.38 3 <10 <10 >4.45 >4.38 4 <10 <10 >4.45 >4.38 5 <10 <10 >4.45 >4.38

TABLE-US-00003 TABLE 3 Effect of 15% CuZn foam material on two types of bacteria: Staphylococcus aureus and Klebsiella pneumoniae. 24-hour contact time Recovery per test Mean Log.sub.10 piece (CFU) Log.sub.10 reductions reductions S. S. S. aureus K. aureus K. aureus K. ATCC pneumoniae ATCC pneumoniae ATCC pneumoniae Sample: Replicate 6538 NCO9633 6538 NCO9633 6538 NCO9633 Inoculum — 2.8 × 10.sup.5 2.4 × 10.sup.5 — — — — (zero time) 15% 1 <10 <10 >4.45 >4.38 >4.45 >4.38 CuZn 2 <10 <10 >4.45 >4.38 Foam 3 <10 <10 >4.45 >4.38 4 <10 <10 >4.45 >4.38 5 <10 <10 >4.45 >4.38

[0064] For samples ‘3% CuZn Foam’ and ‘15% CuZn Foam’ both bacterial strains were seen to be reduced in number by >4 log over a 24-hour contact time. This was compared to the sample ‘0% CuZn Foam’, which displayed no significant antibacterial activity against either test organism.

Example 2

[0065] Test of the Antimicrobial Material on the Fungus Candida albicans.

[0066] The test organism was prepared to approximately 1×10.sup.6 CFU/mL in 0.85% NaCl. For each sample, five replicate test pieces were inoculated with an appropriate volume of the test organism (Table 2). The inocula were enumerated using pour-plates of Sabouraud Dextrose Agar (SDA) at the point of inoculation. The inoculated samples were then placed in an incubator at 24° C.±1° C. for 1, 8 or 24 hours at >95% humidity. Following the required exposure times, the inoculated test pieces were aseptically removed to 9 mL of diluent. This was vigorously shaken to ensure thorough resuspension of any remaining test organisms. The resulting suspension was plated out in SDALT (SDA supplemented with 0.3% soya lecithin and 3% Tween 80). Plates were incubated at 24° C.±1° C. for at least five days. For the negative control, the samples were inoculated with an appropriate volume (Table 2) of sterile 0.85% NaCl and incubated and analysed in the same way as the test samples.

TABLE-US-00004 TABLE 4 Sample inoculum volumes Sample Inoculum volume 0% CuZn Foam  1.0 mL 2% CuZn Foam  300 μL 3% CuZn Foam 1.25 mL

TABLE-US-00005 TABLE 5 Effect of 0% CuZn Foam material on the fungus Candida albicans. 1, 8 or 24 hour contact times with Candida albicans ATCC 10231 Log10 reductions of Recovery per test piece Log10 reductions mean recovery Sample: Replicate 1 hr 8 hr 24 hr 1 hr 8 hr 24 hr 1 hr 8 hr 24 hr Inoculum — 1.2 × 10.sup.6 — — (zero time) Positive — 9.1 × 10.sup.5 9.6 × 10.sup.5 1.5 × 10.sup.6 0.12 0.10 0 0.12 0.10 0 control Negative — <10 <10 <10 — — — — — — control 0% CuZn 1 5.7 × 10.sup.5 4.1 × 10.sup.5 >10.sup.6 0.32 0.47 <0.08 0.47 0.32 <0.10 Foam 2 4.0 × 10.sup.5 6.0 × 10.sup.5 >10.sup.6 0.48 0.30 <0.08 3 4.3 × 10.sup.5 7.1 × 10.sup.5 7.4 × 10.sup.5 0.45 0.23 0.21 4 2.8 × 10.sup.5 5.9 × 10.sup.5 >10.sup.6 0.63 0.31 <0.08 5 3.8 × 10.sup.5 5.8 × 10.sup.5 >10.sup.6 0.50 0.32 <0.08

TABLE-US-00006 TABLE 6 Effect of 2% CuZn Foam material on the fungus Candida albicans. 1, 8 or 24 hour contact times with Candida albicans ATCC 10231 Log10 reductions of Recovery per test piece Log10 reductions mean recovery Sample: Replicate 1 hr 8 hr 24 hr 1 hr 8 hr 24 hr 1 hr 8 hr 24 hr Inoculum — 3.6 × 10.sup.5 — — (zero time) Negative — <10 <10 <10 — — — — — — control 2% CuZn 1 1.2 × 10.sup.2 1.0 × 10.sup.1 <10 3.48  4.56 >4.56 3.22 >4.56 >4.56 Foam 2 1.9 × 10.sup.2 <10 <10 3.28 >4.56 >4.56 3 2.7 × 10.sup.2 <10 <10 3.13 >4.56 >4.56 4 2.4 × 10.sup.2 <10 <10 3.18 >4.56 >4.56 5 3.0 × 10.sup.2 <10 1.0 × 10.sup.1 3.08 >4.56  4.56

TABLE-US-00007 TABLE 7 Effect of 3% CuZn Foam material on the fungus Candida albicans. 1, 8 or 24 hour contact times with Candida albicans ATCC 10231 Log10 reductions of Recovery per test piece Log10 reductions mean recovery Sample: Replicate 1 hr 8 hr 24 hr 1 hr 8 hr 24 hr 1 hr 8 hr 24 hr Inoculum — 1.5 x10.sup.6 — — (zero time) Negative — <10 <10 <10 — — — — — — control 3% CuZn 1 4.3 × 10.sup.5 1.0 × 10.sup.1 <10 0.55 5.18 >5.18  0.66 >3.98 >5.18 Foam 2 3.9 × 10.sup.5 <10 1.0 × 10.sup.1 0.59 >5.18  5.18 3 3.9 × 10.sup.5 7.0 × 10.sup.1 <10 0.59 4.33 >5.18  4 1.7 × 10.sup.5 3.5 × 10.sup.2 1.0 × 10.sup.1 0.95 3.64 5.18 5 2.8 × 10.sup.5 3.6 × 10.sup.2 <10 0.73 3.62 >5.18 

[0067] For samples ‘0% CuZn Foam’ no significant reduction in the numbers of Candida albicans was observed after 1, 8 or 24 hour contact times at 24° C. For sample ‘2% CuZn Foam’ a greater than 3 log reduction in the numbers of Candida albicans was observed after a contact time of 1 hour; a greater than 4 log reduction in the numbers of Candida albicans was observed after 8 hour or 24 hour contact times at 24° C. For sample ‘3% CuZn Foam’ no significant reduction in the numbers of Candida albicans was observed after a 1 hour contact time; a greater than 3 log reduction in the numbers of Candida albicans was observed after 8 hours at 24° C.; a greater than 5 log reduction in the number of Candida albicans was observed after 24 hours at 24° C.

Example 3

[0068] Test of the Antimicrobial Material on the Bovine Corona Virus (BCV) Strain L9.

[0069] For the preparation of the material, pieces of 1×1 cm were cut in sterile conditions and after a folding step transferred to an Eppendorf cup. For preparation of test virus solution, U373 cells were cultivated. For virus production, BCV strain L9 was added to the prepared monolayer. After an incubation period of 24-48 hours, cells were lysed by a rapid freeze/thaw cycle. Cellular debris was removed and the supernatant was directly used as the test virus suspension. Infectivity was determined by means of end point dilution titration using the microtitre process. The virucidal activity of the treated material was evaluated by calculating the decrease in titre in comparison with the virucidal activity of the non-treated material.

TABLE-US-00008 TABLE 8 Virus titres (bovine coronavirus) in the 10 fold assay with treated (novel green/white nylon copper infused fabric) and non-treated material (reference: Tork Premium Special Tucher) after 60 minutes exposure time. Dilutions (log.sub.10) Product 1 2 3 4 5 6 7 8 9 10 Copper ≤1.50 ± ≤1.50 ± ≤1.50 ± ≤1.50 ± ≤1.50 ± ≤1.50 ± ≤1.50 ± ≤1.50 ± ≤2.00 ± ≤1.50 ± material 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.00 Reference  2.83 ±  3.25 ±  2.63 ±  2.88 ±  3.38 ±  3.13 ±  2.88 ±  3.88 ±  2.63 ±  2.63 ± material 0.37 0.33 0.433 0.37 0.25 0.37 0.37 0.37 0.41 0.25

[0070] After a contact time of 60 minutes, only one material residual virus could be measured with the novel green/white nylon copper infused fabric. In contrast, examining the non-treated materials residual virus could be detected in all cases. The following mean values resulted: ≤1.55±0.04 (novel green/white nylon copper infused fabric) and 2.98±0.12 (reference). A difference of 1.43 log.sub.10 steps between both materials was visible based on the 10 fold determinations after 60 minutes exposure time.